Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis.
Jonathan E LeemanKee-Young ShinYu-Hui ChenRaymond H MakPaul L NguyenAnthony V D'AmicoNeil E MartinPublished in: Cancer (2023)
Magnetic resonance imaging-guided daily adaptive prostate stereotactic radiation (MRg-A-SBRT) is a treatment that may allow for delivery of prostate radiation more precisely than other radiotherapy techniques, but it is unknown whether this reduces side effects compared to standardly used computed tomography-guided SBRT (CT-SBRT). In this systematic review and meta-analysis combining data from 29 clinical trials including 2547 patients, it was found that the risk of short-term urinary side effects was reduced by 44% and the risk of short-term bowel side effects was reduced by 60% with MRg-A-SBRT compared to CT-SBRT.
Keyphrases
- radiation therapy
- computed tomography
- contrast enhanced
- magnetic resonance imaging
- prostate cancer
- radiation induced
- dual energy
- magnetic resonance
- positron emission tomography
- image quality
- clinical trial
- locally advanced
- benign prostatic hyperplasia
- early stage
- end stage renal disease
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- prognostic factors
- oxidative stress
- electronic health record
- open label
- study protocol
- drug induced
- patient reported
- brain metastases
- mechanical ventilation